Assembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngine

Assembly Biosciences (NASDAQ:ASMB) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other analysts have also recently weighed in on ASMB. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday. B. Riley assumed coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 target price on the stock. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, Jefferies Group assumed coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.25.

Assembly Biosciences (ASMB) traded up $0.77 during trading hours on Friday, reaching $46.57. 112,226 shares of the company traded hands, compared to its average volume of 153,489. The company has a market capitalization of $921.99, a PE ratio of -15.68 and a beta of 0.77. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $52.37.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.17. The company had revenue of $2.66 million during the quarter, compared to the consensus estimate of $1.25 million. sell-side analysts forecast that Assembly Biosciences will post -3.22 EPS for the current year.

In other news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $49.37, for a total transaction of $49,370.00. Following the sale, the director now owns 20,465 shares in the company, valued at approximately $1,010,357.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 3,000 shares of company stock worth $141,270. Company insiders own 19.60% of the company’s stock.

Several hedge funds have recently made changes to their positions in ASMB. Nationwide Fund Advisors bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $161,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,203 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $212,000. Wells Fargo & Company MN bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $213,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Assembly Biosciences by 15,448.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 11,123 shares in the last quarter. Hedge funds and other institutional investors own 61.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/03/assembly-biosciences-asmb-stock-rating-upgraded-by-valuengine.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply